Novartis's Cosentyx Fails To EXCEED Humira in PsA
'Narrowly Missed' Statistical Significance
Executive Summary
The Swiss major's immunology head tells Scrip that while Cosentyx was unable to beat Humira on the 20% improvement scale for symptoms in psoriatic arthritis patients, the totality of the data from the EXCEED study should sway clinicians to use the IL-17 inhibitor as a first-line treatment.
You may also be interested in...
AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Novartis Eyes Fourth Approval For Cosentyx
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.
Tremfya And Taltz Provide PsA Highlights At EULAR
The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.